CTLA-4-directed Blocking Antibody [EPC]

48231 reported adverse events

Drugs of this class: IPILIMUMAB TREMELIMUMAB

These side effects are most commonly reported by patients taking drugs of the CTLA-4-directed Blocking Antibody [EPC] class:

# Side effect Count
0 DEATH 4988
1 MALIGNANT NEOPLASM PROGRESSION 4144
2 DIARRHOEA 3454
3 OFF LABEL USE 2701
4 COLITIS 2511
5 PYREXIA 2324
6 RASH 1988
7 FATIGUE 1777
8 NAUSEA 1478
9 INTENTIONAL PRODUCT USE ISSUE 1352
See all common reactions for CTLA-4-directed Blocking Antibody [EPC]

Drugs of the CTLA-4-directed Blocking Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HYPOPHYSITIS 1102 0.5474
1 LYMPHOCYTIC HYPOPHYSITIS 148 0.5362
2 AUTOIMMUNE COLITIS 290 0.4496
3 IMMUNE-MEDIATED HYPOPHYSITIS 199 0.4412
4 IMMUNE-MEDIATED ENTEROCOLITIS 1330 0.3613
5 IMMUNE-MEDIATED DERMATITIS 347 0.3442
6 IMMUNE-MEDIATED HEPATITIS 608 0.2975
7 IMMUNE-MEDIATED THYROIDITIS 135 0.2733
8 HYPOPITUITARISM 466 0.2677
9 IMMUNE-MEDIATED HEPATIC DISORDER 514 0.2633
See all enriched reactions for CTLA-4-directed Blocking Antibody [EPC]